Patients who received the drug letermovir after hematopoietic stem cell transplantation had fewer cytomegalovirus infections than those who received a placebo, according to a study in The New England Journal of Medicine. All-cause prophylaxis failure was low and infections were detected sooner among study participants who received the highest doses.

Related Summaries